← Back to Search

Behavioural Intervention

3D Kidney model enhanced patient education for Chronic Kidney Disease

N/A
Waitlist Available
Research Sponsored by Hilary L Surratt, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Ages 18 and older
* Seeking medical care in study location
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and post intervention, approximately 1 hour
Awards & highlights
No Placebo-Only Group

Summary

High blood pressure has a different rate effect on many minoritized individuals. African Americans, as a result of high blood pressure, are six times more likely to go through kidney failure compared to white counterparts. Hispanic communities are also disproportionately affected by high blood pressure and, unfortunately, generally have lower knowledge about the effects on the kidneys as well. Unfortunately, many minorized and underserved communities are affected by the weight of the social determinants of health, i.e., housing, education, food, health care, etc., that contribute to large disparities in health outcomes. These factors lead to poor care management, less ability to manage care effectively, and disengagement from care. Health education is vital to recognizing and communicating with minoritized patients with hypertension-induced chronic renal disease. As the patient's knowledge of the condition grows, this can significantly influence the trust between clinicians and patients. Effective and patient-centered education can inspire patients to be proactive in their prevention strategies with clinicians. This study's overall goal is to assess the utility of a novel patient education tool (3D-printed healthy kidney and diseased kidney models) in optimizing patient education for underserved populations who have hypertension with a potential lead to hypertension-induced chronic renal disease.

Who is the study for?
This trial is for individuals from minoritized communities with high blood pressure that may lead to chronic kidney disease. It aims to educate those who might not have extensive knowledge about the impact of hypertension on kidneys, focusing on African American and Hispanic populations affected by health disparities.
What is being tested?
The study is testing a new patient education tool: 3D-printed models of healthy and diseased kidneys. Participants will receive standard medical treatment for high blood pressure and kidney issues, plus education using these models to see if it improves understanding and management of their condition.
What are the potential side effects?
Since this trial focuses on education rather than medication or invasive procedures, there are no direct side effects from the intervention itself. However, participants' emotional or psychological responses to learning about their health conditions in detail could vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and post intervention, approximately 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and post intervention, approximately 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in participant confidence for kidney disease management

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 3D Kidney model enhanced patient educationExperimental Treatment1 Intervention
patient education with 3D model
Group II: Standard clinical care/TAUActive Control1 Intervention
standard clinician-led patient education

Find a Location

Who is running the clinical trial?

University of KentuckyOTHER
192 Previous Clinical Trials
223,522 Total Patients Enrolled
Hilary L Surratt, PhDLead Sponsor
2 Previous Clinical Trials
504 Total Patients Enrolled
~67 spots leftby Jul 2025